Compare Domino's Pizza, Inc. (DPZ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Moderna, Inc. — how do they compare? Domino's Pizza, Inc. trades at $309.36 (market cap $10.21B), while Moderna, Inc. trades at $225 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 7.7× Domino's Pizza, Inc.'s market cap, and Domino's Pizza, Inc. pays a 2.58% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Moderna, Inc. for 59 Days on average.
| DPZ | MRNA | |
|---|---|---|
Market Cap | $10.21B | $78.65B |
Volume | 916,737 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $203.46 |
52-Week Low | $282.89 | $22.36 |
Typical Hold Time | 106 Days | 59 Days |
Enterprise Value | $15.17B | $74.80B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DPZ trades at $308.65, up 1.83% today, with a bullish technical signal but recent earnings misses. Revenue grew to $4.94B in 2025 with a net income margin of 11.86%, though the company carries significant debt. Analyst consensus is a Buy with a $373 price target, but news highlights concerns over dividend growth and store closures.
The outlook is mixed: strong profitability and analyst support suggest upside, but high debt and recent underperformance pose risks. Investors should weigh solid fundamentals against execution challenges and macroeconomic pressures on the restaurant sector.
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
